What changed: r3 to r4
September 28 review: recorded the Blue Moon warrant, the Tungsten West offtake through 2034 and the agreed $124.75M Masan High-Tech Materials stake as risks and checkpoints, with a limitation that none of the three is in the operating-model cells. No forecast cell changed.
Retrieval clocks and internal hashes are excluded. Changed source or accounting definitions are not automatically an economic restatement. The authored reason describes the destination revision.
| Field | Before | After |
|---|---|---|
| /meta/as_of | 2026-09-19 | 2026-09-28 |
| /meta/research_reviewed_at | 2026-09-19 | 2026-09-28 |
| /meta/revision | 3 | 4 |
| /research/change_note | Added September completed/conditional funding split, preferred PIK, stockpile delivery limits and German price sensitivity. | September 28 review: recorded the Blue Moon warrant, the Tungsten West offtake through 2034 and the agreed $124.75M Masan High-Tech Materials stake as risks and checkpoints, with a limitation that none of the three is in the operating-model cells. No forecast cell changed. |
| /research/checkpoints/0/event | Staged financing | Masan High-Tech Materials purchase |
| /research/checkpoints/0/timing | First subsequent tranche window from March 2027 | Agreement September 23, 2026; closing timing unconfirmed |
| /research/checkpoints/0/watch | Verify conditions and actual receipts rather than assuming the full commitment is cash. | Confirm closing, the $124.75M cash outflow, the accounting for a 4.99% stake with board rights, and any dividend received. Until closing the commitment is a use of cash with a $24.95M break fee, not an asset. |
| /research/checkpoints/1/event | German acquisition | Tungsten West offtake deliveries |
| /research/checkpoints/1/timing | Q1 calendar 2027 expected closing | Annual purchases from 2027 through December 31, 2034 |
| /research/checkpoints/1/watch | Obtain final price, pension/working-capital values and acquired financials. | Obtain volume, price basis and the minimum targets that release the 50% production allocation; treat contracted concentrate as input supply, not sales. |
| /research/checkpoints/2/event | Stockpile and new supply | Blue Moon warrant window |
| /research/checkpoints/2/timing | Each delivery-order/project update | Exercisable from six months after September 21, 2026, for three years |
| /research/checkpoints/2/watch | Separate the ceiling, accepted orders, qualified supply and recognized deliveries. | Track exercise, the beneficial-ownership cap and any change to the CAD35M investment commitment the warrant was issued for. |
| /research/checkpoints/3/date_status | None | estimated |
| /research/checkpoints/3/event | None | Staged financing |
| /research/checkpoints/3/timing | None | First subsequent tranche window from March 2027 |
| /research/checkpoints/3/watch | None | Verify conditions and actual receipts rather than assuming the full commitment is cash. |
| /research/checkpoints/4/date_status | None | estimated |
| /research/checkpoints/4/event | None | German acquisition |
| /research/checkpoints/4/timing | None | Q1 calendar 2027 expected closing |
| /research/checkpoints/4/watch | None | Obtain final price, pension/working-capital values and acquired financials. |
| /research/checkpoints/5/date_status | None | estimated |
| /research/checkpoints/5/event | None | Stockpile and new supply |
| /research/checkpoints/5/timing | None | Each delivery-order/project update |
| /research/checkpoints/5/watch | None | Separate the ceiling, accepted orders, qualified supply and recognized deliveries. |
| /research/economics | H1 revenue was $122.4M and CFO negative $7.6M, with inventory absorbing $32.8M. Net capital spending was $3.1M after grants; July cash was $66.1M. Q2 management attributed about 55% of sales growth to net demand and the remainder to metal-price effects. September 14 brought $200M actual preferred funding under a $450M commitment; remaining $250M is conditional in staged $50M tranches. Preferred PIK accrues at 5.5% and warrants can represent up to 19.9% post-transaction ownership. The DLA agreement has a $2B ceiling and $150M minimum over a five-year ordering period, not immediate revenue. Domestic investment above $165M, controlled Springer plant work and separate raw-material/minority investments require cash. The German asset purchase is expected in Q1 calendar 2027, but final price depends on metal inventory and pension adjustments. | H1 revenue was $122.4M and CFO negative $7.6M, with inventory absorbing $32.8M. Net capital spending was $3.1M after grants; July cash was $66.1M. Q2 management attributed about 55% of sales growth to net demand and the remainder to metal-price effects. September 14 brought $200M actual preferred funding under a $450M commitment; remaining $250M is conditional in staged $50M tranches. Preferred PIK accrues at 5.5% and warrants can represent up to 19.9% post-transaction ownership. The DLA agreement has a $2B ceiling and $150M minimum over a five-year ordering period, not immediate revenue. Domestic investment above $165M, controlled Springer plant work and separate raw-material/minority investments require cash. The German asset purchase is expected in Q1 calendar 2027, but final price depends on metal inventory and pension adjustments. Three later filings add commitments without new revenue. On September 21 Elmet issued Blue Moon Metals an unregistered warrant for 1,166,970 shares at $21.423, exercisable from six months after issue for three years, with a 4.99% beneficial-ownership cap adjustable to 19.99%, as consideration for Blue Moon's binding letter agreement and investment commitment. On September 22 Elmet and Elmet Technologies signed a tungsten concentrate offtake with Drakelands Restoration and Tungsten West through December 31, 2034: annual purchases begin in 2027, Elmet receives at least 50% of qualifying production until minimum targets are met, and holds a 60-day exclusive right to supply the Defense Logistics Agency; no price or volume is stated in the filing. On September 23 Elmet agreed to buy 55,138,174 ordinary shares of Masan High-Tech Materials, a 4.99% stake, from Masan Horizon for $124.75M, with a $24.95M break fee, board nomination rights, an 80% dividend payout target in the shareholders' agreement and an 18-month lock-up; the purchase is an agreement, not a closed transaction. |
| /research/limitations/10 | None | The September 21-23 agreements are disclosed but not yet in the operating-model cells: the $124.75M Masan purchase is a pending cash commitment (with a $24.95M break fee), the Blue Moon warrant is potential dilution, and the Tungsten West offtake carries no stated price or volume. Cash deployment, share count and input-cost cells remain at the September 19 calibration until closing or the next full model review. |
| /research/reviewed_at | 2026-09-19 | 2026-09-28 |
| /research/risks/5 | None | Masan stake: $124.75M of cash for a 4.99% minority holding with a $24.95M break fee and an 18-month lock-up buys dividend participation and a board seat, not tungsten supply or consolidated earnings. |
| /research/risks/6 | None | Blue Moon warrant: 1,166,970 shares at $21.423 add potential dilution on top of the preferred warrants; the offtake from Tungsten West delivers concentrate from 2027 at terms the filing does not price. |
| /sources/4/retrieved | None | 2026-09-28 |
| /sources/4/title | None | September 22 Form 8-K: warrant issued to Blue Moon Metals for its investment commitment |
| /sources/4/url | None | https://www.sec.gov/Archives/edgar/data/2101698/000121390026101918/ea0306130-8k_elmet.htm |
| /sources/5/retrieved | None | 2026-09-28 |
| /sources/5/title | None | September 22 Form 8-K: tungsten concentrate offtake agreement with Tungsten West and Drakelands |
| /sources/5/url | None | https://www.sec.gov/Archives/edgar/data/2101698/000121390026102242/ea0306073-8k_elmet.htm |
| /sources/6/retrieved | None | 2026-09-28 |
| /sources/6/title | None | September 24 Form 8-K: agreement to buy a 4.99% stake in Masan High-Tech Materials |
| /sources/6/url | None | https://www.sec.gov/Archives/edgar/data/2101698/000121390026102840/ea0306067-8k_elmet.htm |
| /thesis/what_changes_it | Track tranche closings, external project cash, inventory, purchase-price adjustments and accepted stockpile orders before upgrading the earnings case. | Track tranche closings, external project cash, inventory, purchase-price adjustments and accepted stockpile orders before upgrading the earnings case. The late-September agreements add three items to watch: the $124.75M Masan High-Tech Materials stake (a minority holding with a break fee, not tungsten supply), the Tungsten West offtake from 2027 (contracted volume, not revenue), and the Blue Moon warrant (dilution alongside the earlier CAD35M commitment). |